Select Language
BAFFR
BAFFR Overview
| English Name | B-cell activating factor receptor | Approved Drugs | 0 |
| Drugs in Clinical Trials | 8 | Target Synonym | BAFFR，B Cell-Activating Factor Receptor，Prolixin，BROMIX，CD268，Tumor Necrosis Factor Receptor Superfamily， Member 13C，Tumor Necrosis Factor Receptor Superfamily Member 13C，BR3，CVID4，CD268 Antigen，BAFF Receptor，B-Cell Activation Factor Receptor，BAFF-R，TNF Receptor Superfamily Member 13C，BLyS Receptor 3，B-Cell-Activating Factor Receptor，TNFRSF13C |
| Highest Development Stage | NDA/BLA | ||
| English Name | B-cell activating factor receptor |
| Target Synonym | BAFFR，B Cell-Activating Factor Receptor，Prolixin，BROMIX，CD268，Tumor Necrosis Factor Receptor Superfamily， Member 13C，Tumor Necrosis Factor Receptor Superfamily Member 13C，BR3，CVID4，CD268 Antigen，BAFF Receptor，B-Cell Activation Factor Receptor，BAFF-R，TNF Receptor Superfamily Member 13C，BLyS Receptor 3，B-Cell-Activating Factor Receptor，TNFRSF13C |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 8 |
| Highest Development Stage | NDA/BLA |
BAFFR Product List
- Product Category
Protein (11)
- Product Status
Launched (12)
- Species
Mouse (3)Human (6)Cynomolgus (1)Rat (1)
- Tag
Fc Tag & Avi Tag (2)Fc Tag (2)Llama IgG Fc Tag (1)His Tag (5)His Tag & Avi Tag (1)
- Conjugate
Biotin-labeled (3)Unconjugated (7)PE Labeled (1)
Total: 11
- 1
- 2
BAFFR Background
BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.
BAFFR Synonyms
BAFFR,TNFRSF13C,BROMIX,CD268,CVID4,prolixin,BAFF-R
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| BAFFR&CD3 BsAb - 01 | PCC | Bispecific | Humanized Mouse,Nanobody | Hematological Malignancy,AutoImmunity | Blood tumor,Autoimmune disease |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ianalumab | VAY-736; NOV-5; NVP-VAY736 | Phase 3 Clinical | Morphosys Ag, Novartis Pharma Ag | Anemia, Hemolytic, Autoimmune; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocytopenia; Scleroderma, Diffuse; Lymphoma, Non-Hodgkin; Hepatitis, Autoimmune; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Multiple Sclerosis; Lupus Nephritis; Idiopathic Pulmonary Fibrosis; Scleroderma, Systemic; Arthritis, Rheumatoid; Sjogren's Syndrome; Lymphoma, B-Cell, Marginal Zone; Purpura, Thrombocytopenic, Idiopathic | Details |
| Anti-BAFFR CAR T therapy(The General Hospital Of Tianjin Medical University) | BAFFR CART | Phase 2 Clinical | The General Hospital Of Tianjin Medical University | Neuromyelitis Optica | Details |
| ESG-206 | ESG-206 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd | Purpura, Thrombocytopenic, Idiopathic; Lymphoma, B-Cell; Neoplasms | Details |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells therapy(Mayo Clinic) | MC10029; MC-10029 | Phase 1 Clinical | Mayo Clinic | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Lymphoma, B-Cell; Autoimmune Diseases | Details | |
| AUR-200 | AUR-200; AUR200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
| JH-013 | JH-013 | Phase 1 Clinical | Biotech Pharmaceuticals Co Ltd | Hematologic Neoplasms; Arthritis, Rheumatoid; Sjogren's Syndrome; Lupus Erythematosus, Systemic | Details |
| BAFFR-CAR T cell therapy (PeproMene Bio Inc) | PMB-CT01; PMB-101 | Phase 1 Clinical | PeproMene Bio Inc, City Of Hope National Medical Center | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute | Details |
- Overview
- Product List
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved